Table 2 Prognostic value of basal type breast cancer delineated by two different immunopanels.
From: Does vimentin help to delineate the so-called 'basal type breast cancer'?
Subgroup | Hazard ratio (95%CI) | p value | 5-year survival rate (95%CI) (%) | p value (log-rank) |
|---|---|---|---|---|
All patients (n = 179) | ||||
'CK5/6 or 14 or 17' | 1.46 (0.90–2.37) | 0.127 |  | 0.124 |
Positive |  |  | 63.5 (50.7–73.8) |  |
Negative |  |  | 75.3 (66.1–82.4) |  |
Vimentin | 1.22 (0.69–2.14) | 0.497 |  | 0.496 |
Positive |  |  | 59.5 (42.1–73.3) |  |
Negative |  |  | 73.9 (65.7–80.4) |  |
'Vimentin or CK5/6 or | 1.73 (1.07–2.81) | 0.026 |  | 0.024 |
14 or 17' | Â | Â | Â | Â |
Positive |  |  | 61.5 (49.3–71.6) |  |
Negative |  |  | 77.6 (68.2–84.5) |  |
Triple negative patients (n = 54) | ||||
'CK5/6 or 14 or 17' | 0.50 (0.21–1.20) | 0.122 |  | 0.115 |
Positive |  |  | 71.8 (54.9–83.3) |  |
Negative |  |  | 52.5 (25.2–74.0) |  |
Vimentin | 0.64 (0.28–1.48) | 0.297 |  | 0.293 |
Positive |  |  | 69.0 (48.8–82.5) |  |
Negative |  |  | 68.0 (46.1–82.5) |  |
'Vimentin or CK5/6 or | 0.56 (0.22–1.45) | 0.234 |  | 0.227 |
14 or 17' | Â | Â | Â | Â |
Positive |  |  | 78.6 (62.9–88.2) |  |
Negative |  |  | 58.3 (27.0–80.1) |  |
Non-triple negative patients (n = 125) | ||||
'CK5/6 or 14 or 17' | 2.61 (1.40–4.84) | 0.002 |  | 0.002 |
Positive |  |  | 50.9 (30.7–67.9) |  |
Negative |  |  | 77.8 (67.9–84.9) |  |
Vimentin* | 3.26 (1.37–7.77) | 0.008 |  | 0.005 |
Positive |  |  | 25.4 (3.8–56.4) |  |
Negative |  |  | 75.2 (66.1–82.2) |  |
'Vimentin or CK5/6 or | 3.04 (1.66–5.56) | <0.001 |  | <0.001 |
14 or 17' | Â | Â | Â | Â |
Positive |  |  | 47.5 (29.1–63.8) |  |
Negative |  |  | 80.1 (70.2–87.0) |  |